SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is surging after announcing a $250 million financing amendment that extends its capital runway through 2028, leading the community to intensely discuss whether this removed dilution risk will ignite a significant short squeeze and a multi-day rally.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is currently trending as investors scrutinize the inauguration of its Eagle Line pilot production facility and a new deep-dive video, sparking intense debate around the company's progress toward scalable solid-state battery manufacturing. Community sentiment is mixed, with bulls highlighting critical advancements and potential OEM partnerships, while skeptics express frustration over continued delays and the stock's performance ahead of its upcoming earnings report.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending as the community eagerly awaits its Q4 earnings report, with widespread belief in the AI-powered lender's significant undervaluation and the potential for a short squeeze amidst a volatile fintech sector. Investors are also noting recent forward flow agreements and debt repurchases as positive indicators, despite broader market concerns.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is actively discussed as it navigates the fallout from retracting its compounded weight-loss pill following regulatory scrutiny and legal threats, with the community sharply divided between those foreseeing a significant short squeeze and a rebound based on its broader telehealth offerings, and others concerned about long-term brand damage and potential liabilities.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF ($IGV) is experiencing intense debate as ongoing AI disruption fears, fueled by new tools like Claude AI, clash with record inflows and trading volume, leading many to view current valuations as a capitulation event and an attractive bottom-picking opportunity.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after Morgan Stanley initiated coverage with a bullish rating, underscoring its strategic acquisitions that double capacity and solidify its position in the rapidly expanding AI/HPC data center market. The community is actively discussing the significant upside potential driven by its unique energy infrastructure and partnerships with hyperscalers, despite ongoing volatility often tied to broader crypto market movements.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending following its launch of fully driverless robotaxi services with Uber in Abu Dhabi, a first outside the U.S., and robust Q3 revenue growth, with the community actively debating whether its stock valuation truly reflects its expanding global footprint, diversified autonomous offerings like WePilot, and growing institutional backing.

Rydex Investments - Invesco CurrencyShares British Pound Sterling Trust

Invesco CurrencyShares British Pound Sterling Trust

The Invesco CurrencyShares British Pound Sterling Trust is trending as recent cooler-than-expected UK CPI data has fueled aggressive market expectations for a Bank of England rate cut, driving bearish sentiment for the pound and highlighting central bank policy divergence.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending amid intense crypto market volatility, with community sentiment sharply divided on whether the recent steep downturn, combined with its highly-debated Super Bowl ad, represents a generational buying opportunity or signals further weakness ahead of anticipated earnings.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is surging after its CEO announced the company is on track for its highest mortgage loan volume and gain-on-sale performance in four years, fueling community discussion around its robust AI Fintech Platform and strong market positioning as interest rates normalize.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2...

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer...

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials PR Newswire AUSTIN...

Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1...

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Announces European Patent Office's Intent...

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market...

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and...

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market...

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets...

&nbsp;1) Butterfly Network (NYSE: BFLY)<ul><li>Background: Butterfly Network is a digital health company pioneering accessible ultrasound technology through its handheld devices, with a mission to democratize high-quality imaging. The Butterfly iQ series has applications in multiple healthcare settings, enabling diagnostic imaging that is portable, affordable, and accessible.</li><li>The News: Butterfly Network recently partnered with HeartFocus to launch an AI-driven training app for cardiac ultrasound, compatible with Butterfly’s portable iQ devices. The app is designed to help healthcare practitioners acquire essential diagnostic skills, even in remote and underserved areas, boosting Butterfly’s appeal to health professionals globally.</li><li>What It Means: This partnership aligns with Butterfly’s vision of expanding ultrasound accessibility, particularly in resource-limited settings. By combining advanced AI-powered education with Butterfly’s handheld devices, the company positions itself as a leader in mobile diagnostics. As demand for accessible healthcare tech grows, Butterfly Network’s innovation could drive significant adoption and revenue growth.</li><li>Stock Reaction: Shares of BFLY rose 3.8%, with trading volume showing heightened interest following the announcement. Investors appear optimistic that AI integrations will boost device uptake, especially among hospitals and clinics focused on remote care.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_20_24_AM_903272e4bf.png" alt="Screenshot 2024-10-29 at 3.20.24 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;2) Gilat Satellite Networks (NASDAQ: GILT)<ul><li>Background: With over 35 years of experience, Gilat Satellite Networks specializes in satellite-based broadband communication solutions, catering to sectors like government, defense, and enterprise. Known for its high-quality and scalable communication systems, Gilat has a strong global reputation in satellite technology.</li><li>The News: Gilat was awarded a $4 million contract from the U.S. Department of Defense to supply DKET 3421 terminals, versatile communication hubs designed for field deployment. These terminals will enhance mission-critical communications, providing secure, mobile connectivity in challenging environments.</li><li>What It Means: This contract reinforces Gilat’s standing as a trusted defense partner, underscoring the value of its portable satellite solutions in national security contexts. Such government contracts bring stable revenue and validate Gilat’s reliability in high-stakes applications.</li><li>Stock Reaction: GILT shares rose 2.9% on above-average volume, reflecting investor confidence in Gilat’s steady pipeline of government contracts.</li><li>Stocktwits Insight: <img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_07_AM_975e4948a4.png" alt="Screenshot 2024-10-29 at 3.21.07 AM.png"></li></ul>&nbsp;3) Power Nickel (TSXV: PNPN)<ul><li>Background: Power Nickel, a Canadian junior exploration company, focuses on nickel and other essential metals used in electric vehicle (EV) batteries. Its primary asset, the Nisk property in Quebec, has yielded high-grade nickel and copper, attracting attention within the green tech sector.</li><li>The News: Power Nickel announced promising drill results from the Lion Zone, with intersections showing high concentrations of copper, gold, and palladium. These results enhance the project’s profile, potentially making Power Nickel a key player in sustainable, North American-based battery metals.</li><li>What It Means: With demand for nickel and battery metals on the rise, Power Nickel’s findings position it well to meet the needs of EV manufacturers seeking local, reliable sources. The results are likely to attract both investment and strategic partnerships within the green energy sector.</li><li>Stock Reaction: PNPN shares fell 2.41%, with trading volume up almost 100% from average indicating growing investor enthusiasm for Power Nickel’s expansion potential.</li><li>Stocktwits Insight: <img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_17_AM_62f6fd842f.png" alt="Screenshot 2024-10-29 at 3.21.17 AM.png"></li></ul>&nbsp;4) Genprex (NASDAQ: GNPX)<ul><li>Background: Genprex is a gene therapy company focused on cancer and diabetes treatments. Its flagship product, Reqorsa, aims to restore tumor-suppressor gene function in cancer patients, showing promise in treating resistant forms of lung cancer.</li><li>The News: Genprex presented positive preclinical data on Reqorsa, showcasing potential effectiveness against KRAS-resistant lung cancer, glioblastoma, and mesothelioma. This data, shared at an international symposium, underscores Reqorsa’s potential as a versatile cancer therapy.</li><li>What It Means: These findings reinforce Genprex’s pipeline credibility and could lay the groundwork for future clinical trials. If further studies replicate these results, Genprex may secure institutional investment as the therapy advances toward regulatory milestones.</li><li>Stock Reaction: GNPX shares surged 38.4% on higher-than-normal volume, as the announcement generated interest among investors.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_26_AM_dab873c609.png" alt="Screenshot 2024-10-29 at 3.21.26 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;5) Monte Rosa Therapeutics (NASDAQ: GLUE)<ul><li>Background: Monte Rosa Therapeutics is developing molecular glue degraders, which eliminate disease-causing proteins. This unique drug class has potential applications in autoimmune diseases, inflammation, and other conditions with few existing treatments.</li><li>The News: Monte Rosa announced a $150 million licensing agreement with Novartis to accelerate its VAV1-directed drug development program. The agreement provides Monte Rosa with significant financial backing to pursue its pipeline.</li><li>What It Means: Partnering with Novartis offers Monte Rosa access to substantial resources and validation for its innovative therapy approach. This collaboration could enhance Monte Rosa’s position within the biotech landscape, while boosting investor confidence.</li><li>Stock Reaction: GLUE shares jumped 93.9% as trading volume spiked, 27,000% reflecting market approval of the deal’s long-term growth potential.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_35_AM_fced9c05f9.png" alt="Screenshot 2024-10-29 at 3.21.35 AM.png"></li></ul>&nbsp;6) Atlas Lithium (NASDAQ: ATLX)<ul><li>Background: Atlas Lithium is a lithium exploration and development company working on the Neves project in Brazil’s “Lithium Valley.” With the global shift toward EVs and renewable energy storage, lithium is in high demand for battery production.</li><li>The News: Atlas secured regulatory permits to proceed with lithium extraction and processing at the Neves site. These approvals allow Atlas to develop a processing plant, positioning it to become a lithium supplier in the rapidly expanding EV battery market.</li><li>What It Means: This milestone accelerates Atlas’s journey to become a key player in the lithium supply chain. As EV adoption grows, Atlas’s Neves project may play a crucial role in meeting global lithium demand.</li><li>Stock Reaction: ATLX shares gained 24.7% on increased trading volume (5x), as investors anticipate the project’s potential impact on Atlas’s valuation.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_43_AM_6743660382.png" alt="Screenshot 2024-10-29 at 3.21.43 AM.png"></li></ul>&nbsp;7)Procept BioRobotics (NASDAQ: PRCT)<ul><li>Background: Procept BioRobotics specializes in robotic systems for urological procedures. Its AquaBeam Robotic System, a minimally invasive treatment for benign prostatic hyperplasia (BPH), has shown significant market growth.</li><li>The News: Procept reported strong Q3 earnings, driven by increased AquaBeam sales and consumables. The company raised its revenue guidance, signaling robust demand and operational growth.</li><li>What It Means: Procept’s earnings beat highlights its competitive edge in surgical robotics, particularly in the high-demand market for BPH treatment. The raised guidance reflects Procept’s confidence in continued market penetration and long-term revenue potential.</li><li>Stock Reaction: PRCT shares rose 32.3% on significant volume (6x), with investors responding positively to the improved financial outlook.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_22_05_AM_0dfbb455f8.png" alt="Screenshot 2024-10-29 at 3.22.05 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion on the WVC Facebook Investor Group</a><a target="_blank" rel="noopener noreferrer nofollow" href="http://www.stocktwits.com/wealthyvc">Follow us on Stocktwits</a>&nbsp;&nbsp;Have a Stock Tip or New Story Suggestion? Email us at: Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Small and Micro-Cap Movers: Key News, Market Reactions, and Insider Chatter

Equity

Today’s most impactful small-cap stock updates, with exclusive rumors, insights, and analysis from StockTwits

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

Genprex Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '24	-$19.50	--	--	N/A
Q3 '24	-$1.23	--	--	N/A
Q2 '24	-$3.00	-$150.00	-4900.00%	MISSED
Q1 '24	-$3.69	--	--	N/A

GNPX
Genprex Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '24

Historical Earnings

Latest GNPX News

GNPXGenprex Inc